Pharming Group N.V.
PHAR
$12.97
-$0.12-0.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 72.45M | 106.53M | 93.22M | 93.22M | 79.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.45M | 106.53M | 93.22M | 93.22M | 79.09M |
| Cost of Revenue | 6.64M | 21.13M | 8.97M | 8.97M | 8.32M |
| Gross Profit | 65.80M | 85.40M | 84.25M | 84.25M | 70.77M |
| SG&A Expenses | 45.53M | 50.67M | 57.25M | 57.25M | 57.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -377.00K | -348.00K | -1.85M | -1.85M | -383.00K |
| Total Operating Expenses | 77.36M | 103.50M | 90.17M | 90.17M | 86.14M |
| Operating Income | -4.91M | 3.03M | 3.05M | 3.05M | -7.04M |
| Income Before Tax | -4.75M | 4.80M | 7.08M | 7.08M | -11.79M |
| Income Tax Expenses | 459.00K | -528.00K | 2.53M | 2.53M | 3.10M |
| Earnings from Continuing Operations | -5.21M | 5.33M | 4.55M | 4.55M | -14.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 144.00K | 144.00K | 169.00K |
| Net Income | -5.21M | 5.33M | 4.69M | 4.69M | -14.72M |
| EBIT | -4.91M | 3.03M | 3.05M | 3.05M | -7.04M |
| EBITDA | -1.80M | 6.24M | 4.28M | 4.28M | -4.46M |
| EPS Basic | -0.01 | 0.01 | 0.01 | 0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | 0.01 | 0.01 | 0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 744.71M | 662.50M | 686.44M | 686.44M | 669.05M |
| Average Diluted Shares Outstanding | 744.71M | 757.14M | 686.44M | 686.44M | 669.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |